INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 440m ago
HOUSE PTR40m ago
SEC 13F40m ago
ROBINHOOD CHAIN40m ago
AW
Corporate insider

Albers Jeffrey W.

DirectorCIK 0001638474

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 3
Max Insider Score26
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
19
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$835K
8,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Director · Aug 10, 2026
26
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$1.05M
10.0K sh
Aug 7, 2026
Aug 10, 2026
traded Aug 7, 2026
+3d
SEC FORM 4

Evidence

3
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

23
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$522K
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence

2
AW
Albers Jeffrey W.Director
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$52K
5,000 sh
Aug 7, 2026Aug 10, 2026
traded Aug 7, 2026
+3dSEC FORM 4

Evidence